Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide
Qianyu Zhang1, Libao Lu1, Li Zhang1
1Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern RenminRoad, Chengdu 610041, China.
Abstract:
[D]-H6L9, as a pH-responsive anti-microbial peptide (AMP), has been evidenced by us to be an excellent choice in tumor microenvironment-responsive delivery as it could render liposomes responsive to the acidified tumor microenvironment. However, [D]-H6L9-modified liposomes could not actively target to tumor area. Therefore, integrin αvβ3-targeted peptide RGD was co-modified with [D]-H6L9 onto liposomes [(R + D)-Lip] for improved tumor delivery efficiency. Under pH 6.3, (R + D)-Lip could be taken up by C26 cells and C26 tumor spheroids (integrin αvβ3-positive) with significantly improved efficiency compared with other groups, which was contributed by both RGD and [D]-H6L9, while RGD did not increase the cellular uptake performance on MCF-7 cells (integrin αvβ3-negative). Results showed that RGD could decrease cellular uptake of (R + D)-Lip while [D]-H6L9 could increase it, implying the role of both RGD and [D]-H6L9 in cellular internalization of (R + D)-Lip. On the other hand, (R + D)-Lip could escape the entrapment of lysosomes. PTX-loaded (R + D)-Lip could further increase the cellular toxicity against C26 cells compared with liposomes modified only with RGD and [D]-H6L9 respectively, and achieve remarkable tumor inhibition effect on C26 tumor models.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Stimuli-Activated
Modified-Release Drug Delivery Systems: Classification
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Rate-Programmed I


